Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
RELA vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Adjunctive treatment for acute musculoskeletal pain due to muscle spasm (FDA approved),Off-label: Tension headaches, fibromyalgia, myofascial pain syndrome
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Adults: 250-350 mg orally 3-4 times daily.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life approximately 20–30 hours; prolonged in elderly and renal impairment
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Hepatic metabolism via CYP2C19 to meprobamate (active); also minor pathways via CYP3A4 and CYP1A2. Meprobamate is further hydroxylated and glucuronidated.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Primarily renal excretion of unchanged drug and metabolites; 70% to 80% eliminated via urine, remainder biliary/fecal
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
99% bound to albumin and alpha-1-acid glycoprotein
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.1–0.2 L/kg; indicates limited distribution in total body water
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 80–90%; Intramuscular: 100%
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
GFR 10-50 m L/min: administer 250 mg every 6-8 hours; GFR <10 m L/min: administer 250 mg every 12-24 hours.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 50% and monitor; Class C: avoid use.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children 2-12 years: 10-20 mg/kg/day divided every 6-8 hours; maximum 1.5 g/day.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Start at lower end of adult dosing (250 mg 3 times daily); monitor for CNS effects and adjust based on renal function.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
None explicitly required by FDA; however, dependence, withdrawal, and abuse potential are significant due to meprobamate metabolite, leading to controlled substance scheduling (Schedule IV).
None
Risk of dependence, withdrawal (including seizures, anxiety, insomnia) after prolonged use; CNS depression (additive with alcohol and other depressants); impaired motor skills; caution in hepatic or renal impairment; elderly patients more sensitive; avoid abrupt discontinuation.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Hypersensitivity to carisoprodol or meprobamate; acute intermittent porphyria; concurrent use with MAO inhibitors (theoretical interaction). Relative: history of substance abuse, severe hepatic or renal disease, poor CYP2C19 metabolizers.
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
No specific food interactions. However, avoid alcohol as it increases sedation and respiratory depression risk.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
Carisoprodol, the active ingredient in RELA, is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and skeletal variants at doses 4-5 times the human dose. There are no adequate and well-controlled studies in pregnant women. First trimester: Risk cannot be ruled out; use only if clearly needed. Second and third trimesters: May cause neonatal withdrawal syndrome or respiratory depression if used near term. Discontinue use if pregnancy occurs.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Carisoprodol and its active metabolite meprobamate are excreted in human breast milk. The milk-to-plasma ratio for meprobamate is approximately 2-4. Based on limited data, a nursing infant would receive about 1-3% of the maternal weight-adjusted dose. Consider the potential for infant sedation or feeding difficulties. Use caution in breastfeeding women, especially with high doses or prolonged use.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
Pharmacokinetic changes in pregnancy (increased volume of distribution, increased renal clearance, altered hepatic metabolism) may increase carisoprodol clearance. Reduce steady-state concentrations; however, no specific dosing adjustments are recommended due to lack of data. Use the lowest effective dose for the shortest duration. Avoid during labor and delivery due to risk of neonatal respiratory depression.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
RELA (carisoprodol) is a centrally acting muscle relaxant metabolized to meprobamate, a controlled substance. Monitor for sedation and abuse potential. Avoid concurrent use with CNS depressants including alcohol. Sudden discontinuation after prolonged use may precipitate withdrawal symptoms.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
This medication may cause drowsiness or dizziness. Do not drive or operate heavy machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this drug.,Take only as prescribed; do not increase dose or duration due to risk of dependence.,Do not stop abruptly after long-term use; consult your doctor for a taper schedule.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about RELA vs CARISOPRODOL, answered by our medical review team.
RELA is a Skeletal Muscle Relaxant that works by RELA (Carisoprodol) is a centrally acting muscle relaxant that modulates GABA-A receptor activity and blocks interneuronal activity in the descending reticular formation and spinal cord, resulting in muscle relaxation without directly affecting the neuromuscular junction. Its metabolite, meprobamate, contributes to anxiolytic and sedative effects.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between RELA and CARISOPRODOL depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of RELA is: Adults: 250-350 mg orally 3-4 times daily.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between RELA and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. RELA is classified as Category C. Carisoprodol, the active ingredient in RELA, is classified as FDA Pregnancy Category C. Animal studies have shown an increased incidence of fetal resorptions and skeletal variants . CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.